Full Breakdown
Children Left Behind in the DRC Ebola Outbreak
9/6/2026, 10:18:44 PM
Outbreak Overview and Child Mortality
Since the Ebola outbreak began in mid-May in the Democratic Republic of Congo (DRC), more than 3,000 people have died. Doctors Without Borders (MSF) notes that the mortality rate for children under five exceeds 60 % — a figure attributed to limited medication options and challenges in diagnosing young patients. MSF’s commentary in *The Lancet* links the heightened risk to weakened immune systems, underlying health conditions, and the difficulty of delivering care in an emergency.
Trial Exclusions and Pediatric Formulations
The EBO-PEP study, which began on July 14 2026, evaluates the oral antiviral obeldesivir as post-exposure prophylaxis for the Bundibugyo Ebola virus. The trial originally excluded children weighing less than 30 kg (?12 years). A protocol amendment will include children over 20 kg, but those under 20 kg remain excluded because no pediatric formulation exists and no data support tablet crushing or dissolution.
An intravenous regimen using remdesivir is available for the youngest patients, but MSF describes a ten-day infusion course as “operationally very difficult” in outbreak settings. Gilead Sciences has signaled willingness to produce a pediatric formulation of obeldesivir, though the timeline for its availability and for a trial using the new formulation remains uncertain.
Cost and Prioritization Concerns
Marc Biot, access coordinator for Europe at Doctors Without Borders, explains that “All of this creates extra costs,” a burden that often leads research institutions and pharmaceutical companies to prioritize adult studies. He adds, “It is faster and it can be cheaper if you only focus on adults,” highlighting a systemic bias that delays pediatric inclusion.
Official Statements & Responses
The organization calls for simultaneous inclusion of children and pregnant women in clinical trials, arguing that emergency contexts shift the balance between protecting vulnerable groups from investigational products and protecting them from a fatal disease.
The World Health Organization’s Global Accelerator for Pediatric Formulations network, established in 2020, is cited as a mechanism to accelerate child-friendly medicine development, but its impact on the current outbreak remains limited.
Verbatim Quotes
- “All of this creates extra costs,” — Marc Biot, access coordinator for Europe at Doctors Without Borders
- “When you're doing a research study, which is not in an emergency, [it makes sense] to protect children and pregnant women from any potential harm of an investigational product,” — Neal Russell, pediatric doctor
Conflicting Reports & Gaps
In May, an American physician treated in Berlin’s Charité hospital received the experimental antibody MBP134 prophylactically, along with his wife and four children. The efficacy of MBP134 in preventing infection in children therefore remains an unverified claim.
What’s Next
Stakeholders are urged to finalize the protocol amendment that would admit children over 20 kg into the EBO-PEP study and to secure a clear, accelerated timeline from Gilead for pediatric obeldesivir production. Accelerated sub-studies and parallel pediatric arms are advocated as essential steps to ensure that children receive the same access to medical countermeasures as adults during the ongoing crisis.
